Renaissance Technologies (RenTech)'s SPRY Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 174,200 shares of ARS Pharmaceuticals, Inc. (SPRY) worth $750,802, representing 0.00% of the portfolio. First purchased in 2021-Q3, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in SPRY, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 302,542 shares. Largest reduction occurred in Q3 2022, reducing 234,899 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s ARS Pharmaceuticals (SPRY) Holding Value Over Time
Track share changes against reported price movement
Quarterly ARS Pharmaceuticals (SPRY) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +174,200 | New Buy | 174,200 | $4.31 |
| Q4 2024 | -15,800 | Sold Out | 0 | $0.00 |
| Q3 2024 | -108,300 | Reduce 87.27% | 15,800 | $14.50 |
| Q2 2024 | +111,500 | Add 884.92% | 124,100 | $8.51 |
| Q1 2024 | -39,400 | Reduce 75.77% | 12,600 | $10.24 |
| Q4 2023 | -85,700 | Reduce 62.24% | 52,000 | $5.48 |
| Q3 2023 | -166,600 | Reduce 54.75% | 137,700 | $3.78 |
| Q2 2023 | -26,300 | Reduce 7.96% | 304,300 | $0.01 |
| Q1 2023 | +19,600 | Add 6.30% | 330,600 | $0.01 |
| Q4 2022 | -3,400 | Reduce 1.08% | 311,000 | $0.01 |
| Q3 2022 | -234,899 | Reduce 42.76% | 314,400 | $5.28 |
| Q2 2022 | -121,243 | Reduce 18.08% | 549,299 | $4.24 |
| Q1 2022 | +302,542 | Add 82.21% | 670,542 | $3.51 |
| Q4 2021 | +251,400 | Add 215.61% | 368,000 | $6.66 |
| Q3 2021 | +116,600 | New Buy | 116,600 | $9.98 |
Renaissance Technologies (RenTech)'s ARS Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased ARS Pharmaceuticals, Inc. (SPRY) in Q3 2021, acquiring 116,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held ARS Pharmaceuticals, Inc. (SPRY) for 15 quarters since Q3 2021.
Renaissance Technologies (RenTech)'s largest addition to ARS Pharmaceuticals, Inc. (SPRY) was in Q1 2022, adding 670,542 shares worth $2.35 M.
According to the latest 13F filing for Q3 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 174,200 shares of ARS Pharmaceuticals, Inc. (SPRY), valued at approximately $750,802.
As of the Q3 2026 filing, ARS Pharmaceuticals, Inc. (SPRY) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in ARS Pharmaceuticals, Inc. (SPRY) was 670,542 shares, as reported at the end of Q1 2022.